MX2018000459A - Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos. - Google Patents

Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos.

Info

Publication number
MX2018000459A
MX2018000459A MX2018000459A MX2018000459A MX2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A
Authority
MX
Mexico
Prior art keywords
nitrogen
containing heterocyclic
heterocyclic compound
production method
compound
Prior art date
Application number
MX2018000459A
Other languages
English (en)
Inventor
Tanaka Tomoyuki
Murakami Tatsuya
Mizumoto Shinsuke
Nagato Yusuke
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of MX2018000459A publication Critical patent/MX2018000459A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención resuelve el problema de proporcionar un método para fabricar industrialmente un compuesto heterocíclico que contiene nitrógeno que tiene una actividad inhibidora de FLT3 excelente y es útil como un ingrediente farmacéutico activo de un agente farmacéutico. Se proporciona un método de fabricación que utiliza un compuesto representado por la fórmula general [14] (en la fórmula, R1 representa un grupo alquilo de C1-6 opcionalmente sustituido y R8 representa un grupo saliente o similar) o una sal de tal compuesto.
MX2018000459A 2015-07-15 2016-07-14 Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos. MX2018000459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015141034A JP6412471B2 (ja) 2015-07-15 2015-07-15 含窒素複素環化合物の製造方法およびその中間体
PCT/JP2016/070758 WO2017010535A1 (ja) 2015-07-15 2016-07-14 含窒素複素環化合物の製造方法およびその中間体

Publications (1)

Publication Number Publication Date
MX2018000459A true MX2018000459A (es) 2018-09-07

Family

ID=57758235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000459A MX2018000459A (es) 2015-07-15 2016-07-14 Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos.

Country Status (21)

Country Link
US (2) US10435377B2 (es)
EP (1) EP3323811B1 (es)
JP (1) JP6412471B2 (es)
KR (1) KR102032140B1 (es)
CN (1) CN107848987B (es)
AU (1) AU2016294197B2 (es)
BR (1) BR112018000759A2 (es)
CA (1) CA2992403C (es)
DK (1) DK3323811T3 (es)
ES (1) ES2729958T3 (es)
HK (1) HK1245268A1 (es)
IL (1) IL256809B (es)
MX (1) MX2018000459A (es)
NZ (1) NZ738953A (es)
PL (1) PL3323811T3 (es)
RU (1) RU2717830C2 (es)
SG (1) SG11201800245QA (es)
TR (1) TR201909774T4 (es)
TW (1) TWI711605B (es)
WO (1) WO2017010535A1 (es)
ZA (1) ZA201800269B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202027749A (zh) 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑
CN112996515A (zh) * 2018-10-31 2021-06-18 富士胶片株式会社 包含抗肿瘤剂的造粒物
CN112996516A (zh) * 2018-10-31 2021-06-18 富士胶片株式会社 包含抗肿瘤剂的医药组合物的包装体
TW202045174A (zh) 2019-02-28 2020-12-16 日商富士軟片股份有限公司 組合醫藥
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928839D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Novel compounds
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
PT2001892E (pt) 2006-03-17 2013-07-04 Ambit Biosciences Corp Compostos de imidazolotiazole para o tratamento de doenças proliferativas
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
CA2713553A1 (en) 2008-02-01 2009-08-06 Akinion Pharmaceuticals Ab Pyrazine derivatives and their use as protein kinase inhibitors
SI2271670T1 (sl) 2008-03-14 2015-01-30 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
EP2300013B1 (en) 2008-05-21 2017-09-06 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
BR112013028281A2 (pt) 2011-05-04 2017-01-10 Forma Tm Llc compostos e composições para inibição de nampt
JP2013157540A (ja) 2012-01-31 2013-08-15 Toshiba Corp 半導体装置およびその製造方法
AU2013250378B2 (en) * 2012-04-17 2016-01-14 Fujifilm Corporation Nitrogen-containing heterocyclic compound or salt thereof
KR101744033B1 (ko) * 2013-10-16 2017-06-07 후지필름 가부시키가이샤 함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제
KR20150056683A (ko) 2013-11-15 2015-05-27 (주) 제일피앤티 대전 방지 필름 및 이를 이용한 쉴드 백
JP6257782B2 (ja) 2014-08-22 2018-01-10 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用

Also Published As

Publication number Publication date
RU2018100967A (ru) 2019-08-16
TW201706254A (zh) 2017-02-16
BR112018000759A2 (pt) 2018-09-04
EP3323811A4 (en) 2018-05-23
AU2016294197B2 (en) 2018-07-26
NZ738953A (en) 2019-06-28
EP3323811B1 (en) 2019-05-08
US10562862B2 (en) 2020-02-18
ZA201800269B (en) 2019-05-29
CN107848987B (zh) 2020-10-23
US10435377B2 (en) 2019-10-08
JP2017019760A (ja) 2017-01-26
AU2016294197A1 (en) 2018-01-25
US20190169133A1 (en) 2019-06-06
RU2018100967A3 (es) 2019-08-16
CN107848987A (zh) 2018-03-27
KR102032140B1 (ko) 2019-10-15
RU2717830C2 (ru) 2020-03-26
EP3323811A1 (en) 2018-05-23
CA2992403C (en) 2019-12-31
WO2017010535A1 (ja) 2017-01-19
CA2992403A1 (en) 2017-01-19
PL3323811T3 (pl) 2019-09-30
US20180127382A1 (en) 2018-05-10
DK3323811T3 (da) 2019-07-22
SG11201800245QA (en) 2018-02-27
KR20180011848A (ko) 2018-02-02
IL256809B (en) 2019-06-30
ES2729958T3 (es) 2019-11-07
JP6412471B2 (ja) 2018-10-24
HK1245268A1 (zh) 2018-08-24
IL256809A (en) 2018-03-29
TWI711605B (zh) 2020-12-01
TR201909774T4 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
PH12016501813A1 (en) 1,3-benzodioxole derivative
MX2018000459A (es) Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos.
MX2018007418A (es) Compuestos de benzamida y sus usos como herbicidas.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12016502358B1 (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
MY194116A (en) Pharmaceutical compounds
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
MX2018014813A (es) Composiciones antibacterianas.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2019004293A (es) Derivados de fenilamina sustituidos en la posicion 4 y uso de los mismos para proteger los cultivos combatiendo los microorganismos fitopatogenos no deseados.
PH12016502568A1 (en) Novel heterocyclic compound
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12017500435A1 (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MX2017005271A (es) Compuestos de nargenicina y sus usos como agentes antibacterianos.
PH12015502060A1 (en) Hydrochloride salts of an antibiotic compound
TN2014000308A1 (en) Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors
WO2016047967A3 (ko) N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제